Kymera Investor Day Presentation Deck
Tumor Volume (mm³)
Mean, ± SEM
Single Dose of KT-253 Leads to Sustained Tumor Regression
Single Dose of KT-253 Achieves
Sustained Tumor Regression
MDM2 Degradation (KT-253, 1 mg/kg) Leads to Fast Increase
in p53, p21, and PUMA (Key Apoptotic Biomarker)
Rs4:11 XGs
3000-
2000
1000-
0-
Vehicle
KT-253, 1 mg/kg
KT-253, 3 mg/kg
KT-253, 10 mg/kg
20
40
Days (Post-randomization)
60
KYMERA ©2021 KYMERA THERAPEUTICS, INC.
% Ratio (Relative to ACTB)
800
600
400
200
p53
1 3 6 24 48
Time, hrs
Oh
% Ratio (Relative to ACTB)
800
KYMERA R&D DAY - December 16th, 2021
600
400
200
p21
-F--Oh
1 3 6 24 48
Time, hrs
% Ratio (Relative to ACTB)
300-
200-
Clinical equivalent doses of small molecule inhibitors have no significant in vivo impact in these
xenograft models
100
PUMA
I
-- Oh
T
1 3 6 24 48
Time, hrs
PAGE 81View entire presentation